

Treatment Naïve, Chronic HCV

Duration and Dose Finding Peginterferon alfa-2a + Ribavirin

Randomized study of low-dose versus weight based ribavirin and 24 versus 48 weeks of therapy

Hadziyannis SJ, et. al. Ann Intern Med. 2004;140:346-55.

Peginterferon alfa-2a + Ribavirin for Chronic HCV

Treatment Duration and Ribavirin Dose

- **Study**

- Randomized, double-blind trial

- **Subjects**

- N = 1311 with chronic hepatitis C (1284 treated)
- Treatment naïve adult patients; 58% genotype 1
- Serum ALT above upper limit of normal x prior 6 months

- **Regimens**


- Peginterferon alfa-2a: 180 µg/wk + Ribavirin: 800 mg/day x 24 wks
- Peginterferon alfa-2a: 180 µg/wk + *Ribavirin: 1000-1200 mg/day x 24 wks
- Peginterferon alfa-2a: 180 µg/wk + Ribavirin: 800 mg/d x 48 weeks
- Peginterferon alfa-2a: 180 µg/wk + *Ribavirin: 1000-1200 mg/day x 48 wks

- **Primary Endpoint**

- Undetectable serum HCV RNA at end of treatment (ETR)
- Undetectable serum HCV RNA 24 wks after cessation of treatment (SV)

*Ribavirin dose: 1000 mg/day for Wt <75 kg, 1200 mg/day for Wt ≥75 kg


Peginterferon alfa-2a + Ribavirin for Chronic HCV Treatment Duration and Ribavirin Dose



Peginterferon alfa-2a + Ribavirin for Chronic HCV

Treatment Duration and Ribavirin Dose


SVR24 Rates, by Regimen



Peginterferon alfa-2a + Ribavirin for Chronic HCV

Treatment Duration and Ribavirin Dose

Rates of SVR with Different Peginterferon + Ribavirin Regimens



Peginterferon alfa-2a + Ribavirin for Chronic HCV Treatment Duration and Ribavirin Dose

Conclusion: “Treatment with peginterferon-alpha2a and ribavirin may be individualized by genotype. Patients with HCV genotype 1 require treatment for 48 weeks and a standard dose of ribavirin; those with HCV genotypes 2 or 3 seem to be adequately treated with a low dose of ribavirin for 24 weeks.”

This slide deck is from the University of Washington's *Hepatitis C Online* and *Hepatitis Web Study* projects.

Hepatitis C Online
www.hepatitisc.uw.edu

Hepatitis Web Study
<http://depts.washington.edu/hepstudy/>

Funded by a grant from the Centers for Disease Control and Prevention.